Given the fact that existing inhibitors targeting KHK have been tested in clinical trials for nonalcoholic steatohepatitis (NASH), it would be of interest to analyze their effects as adjuvant therapies on PDAC patients. This evidence concerns the gene KHK and metabolic dysfunction-associated steatohepatitis.